Transforming Cancer Monitoring

At Oncobit, we aim to improve patient outcomes with high-precision and cutting-edge cancer monitoring solutions.

Our Mission

Enabling personalized cancer care

We use state-of-the-art technologies to develop cancer-specific monitoring tests and provide physicians with optimal therapy-decision support. Based on a simple blood sample, we offer innovative and robust solutions to closely, precisely and reliably monitor cancer and treatment response. This ensures that patients receive the best possible medical care at optimal cost efficiency.

Learn more about Oncobit

Our Solutions

Specific and sensitive tools for an optimal cancer therapy management

Our solutions provide clinicians with advanced molecular insights for precise cancer monitoring and therapy optimization.

Oncobit™ PM is a data-driven cancer monitoring platform for the sensitive and quantitative detection of specific cancer markers in circulating tumor-derived DNA (ctDNA) from the blood. It consists of cancer specific reagents and a cloud-based analysis software for automatic data interpretation and reporting. This ensures that clinicians receive an unbiased and clear report in a timely manner.

Learn more about our solutions

Our Journey


Oncobit PM Established at 3 Leading Cancer Centers in Germany

We are proud to share that our Oncobit™ PM ctDNA analysis tests are now in use at three prominent cancer centers across Germany, including the University Medical Center Hamburg-Eppendorf (UKE) led by Prof. Christoffer Gebhardt and the Hauttumorcentrum Charité (HTCC) Charité under the guidance of Prof. Thomas Eigentler. Our advanced Oncobit PM tests play a pivotal role in addressing various issues related to cancer monitoring. Specifically, these esteemed institutions will utilize our tests to generate crucial clinical utility data. This data will not only contribute to the advancement of medical knowledge, but will also enhance patient care by providing valuable insights into cancer management. By establishing our test at these leading study sites, we are pushing the boundaries of cancer research and treatment strategies. Together with UKE Hamburg and the Hauttumorcentrum Charité (HTCC), we're committed to making a positive impact on patient outcomes and contributing to the future of personalized medicine.

Oncobit announces partnership with Immunocore to advance therapy response analysis in clinical trials

We are thrilled to announce that we have signed a service agreement with Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. This collaboration aims to improve the use and understanding of circulating tumor DNA (ctDNA) analysis as a reliable and real time therapy response marker in clinical trials.

Read more

Exciting collaboration with the National Cancer Institute and Klaipeda University Hospital in Lithuania for the BIOMELKID study.

We are delighted to announce that Oncobit is collaborating with the National Cancer Institute (NCI) on the BIOMELKID trial. Our joint mission: To identify predictive and prognostic biomarkers in metastatic melanoma patients undergoing immunotherapy. Professor Vincas Urbonas and his team at the NCI are leading this impactful project focused on the study of ctDNA in melanoma patients. With our Oncobit PM digital PCR solutions, we are pleased to provide a powerful tool to reliably quantify ctDNA. Our shared goal is to unlock the secrets of circulating tumor DNA to better understand disease progression and treatment response. Aiming to improve patient care!


Oncobit’s tests provide critical decision support in the treatment and monitoring of advanced melanoma patients.

Prof. Dr. med. Reinhard Dummer, Department of Dermatology USZ, Head of the Skin tumor center, Expert for the Comprehensive Cancer Center Zürich

Our Partners & Supporters